Characteristics of COVID-19 Infection in a Hospitalized Autoimmune Hepatitis Patient.
Vanessa Duarte da CostaWilian Jean WiggersClaudia Alexandre Pontes IvantesRodrigo Jardim Monteiro da FonsecaAlberto Martín Rivera DávilaOtacilio C MoreiraBeatriz Iandra da Silva FerreiraVanessa Salete de PaulaLucas Lima da SilvaAlanna Calheiros SantosLivia Melo VillarPublished in: Pathogens (Basel, Switzerland) (2022)
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a major public health worldwide. Hepatic dysfunction has been seen in patients with COVID-19 and could be related to a viral cytopathic effect, an exacerbated immune reaction, or drug-induced liver damage. Currently, routine modification of immunosuppressive therapy in patients with autoimmune hepatitis (AIH) before and after SARS-CoV-2 infection remains an important topic to be discussed. However, there is little evidence about this thematic to support any recommendation. Here, we described a case report in which the use of an immunosuppressive drug by a patient with diagnosed AIH might have influenced the COVID-19 clinical course with altered laboratory hematological and biochemical parameters during infection.